JPRN-UMIN000012455招募中2 期
Phase II trial of cisplatin and TS-1 with radiotherapy for patients with locally advanced N2 non-small cell lung cancer - Phase II trial of cisplatin and TS-1 with radiotherapy for patients with locally advanced N2 non-small cell lung cancer
Itabashi central medical center0 个研究点目标入组 24 人开始时间: 2013年12月2日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) SVC syndrome 2)Active infection more than and equal to grade 2 3) Continuous watery diarrhea 4) Significant comorbid disease such as paresis of intestine, ileus, interstitial pneumonia, lung fibrosis, uncontrolled diabetes mellitus, cardiac failure, renal failure, hepatic failure, active gastrointestinal ulcer, myocardial infarction and angina pectoris within 6 months, other uncontrolled disease 5) Continuous administration of a steroid 6) Active concomitant malignancy except carcinoma in situ, intramucosal carcinoma or cancer with more than 5 year disease free 7) Pregnant status or lactation 8) Uncontrolled psychiatric disease 9) Patients required for continuing steroid therapy 10) Severe drug allergy 11) Being treated with flucytosine. 12)Participation in other registration trial before randomization in this trial 13) Any patients judged by the investigator to be unfit to participate in the study
研究者
相似试验
已完成
2 期
A phase II study of cisplatin with TS-1 for patients with cancer of primary unknowJPRN-C000000271Department of Medical Oncology, Kinki University School of Medicine45
已完成
2 期
Phase II trial of TS-1 and cisplatin in patients with Carcinoma of Unknown Primary Sites (KMOG 0607)Carcinoma of Unknown Primary SitesJPRN-UMIN000001364Kyushu Medical Oncology Group38
进行中（未招募）
1 期
Randomized Phase II study of chemotherapy (cisplatin) plus radiotherapy (RT) versus immunotherapy durvalumab or immunotherapy, durvalumab and tremelimumab, given with and/or after RT in patients with advanced cancer of the oropharynx that contains the human papilloma virusEUCTR2019-000308-13-BEEuropean Organisation for Research and Treatment of Cancer (EORTC)180
进行中（未招募）
1 期
Randomized Phase II study of chemotherapy (cisplatin) plus radiotherapy (RT) versus immunotherapy durvalumab or immunotherapy, durvalumab and tremelimumab, given with and/or after RT in patients with advanced cancer of the oropharynx that contains the human papilloma virusOropharyngeal Squamous Cell CarcinomaMedDRA version: 20.1Level: LLTClassification code 10079785Term: Oropharyngeal squamous cell carcinoma stage IVSystem Organ Class: 100000004864EUCTR2019-000308-13-ITEuropean Organisation for Research and Treatment of Cancer (EORTC)180
进行中（未招募）
1 期
Randomized Phase II study of chemotherapy (cisplatin) plus radiotherapy (RT) versus immunotherapy durvalumab or immunotherapy, durvalumab and tremelimumab, given with and/or after RT in patients with advanced cancer of the oropharynx that contains the human papilloma virus.EUCTR2019-000308-13-ESEuropean Organisation for Research and Treatment of Cancer (EORTC)180